Orchid Pharma's amalgamation with Dhanuka Laboratories is now effective from July 10, 2026. Dhanuka Laboratories will be dissolved, and Orchid Pharma's capital structure has been updated. The share exchange ratio is set at 161:5.
Orchid Pharma and Dhanuka Laboratories Amalgamation Scheme Becomes Effective
Effective July 10, 2026, Orchid Pharma Limited's scheme of amalgamation with Dhanuka Laboratories Limited (DLL) is now in effect.
Reader Takeaway: Successful consolidation achieved; investors to note share swap details and record date.
What Just Happened
The amalgamation scheme, previously approved, has met all conditions and is now officially effective. Dhanuka Laboratories Limited will be dissolved without being wound up as part of this consolidation. The operational integration of both entities dates back to the appointed date of April 1, 2024.
Why This Matters
This development signifies the completion of a significant corporate restructuring for Orchid Pharma. It will lead to a combined entity with updated share capital structure and operational synergies. Investors holding shares in Dhanuka Laboratories will now be entitled to shares in Orchid Pharma based on the approved exchange ratio.
The Backstory
The scheme of amalgamation was initiated to consolidate operations and potentially create a stronger combined entity. The process involved regulatory approvals and fulfilling all necessary conditions for effectiveness.
What Changes Now
Dhanuka Laboratories Limited ceases to exist as a separate entity, merging into Orchid Pharma. The authorized share capital of Orchid Pharma has been revised to ₹164.51 crore (₹16,451 lakh), comprising 16,45,10,000 equity shares of ₹10 each. The record date for determining share entitlement is July 23, 2026.
Share Exchange Details
Shareholders of Dhanuka Laboratories will receive 161 fully paid-up equity shares of Orchid Pharma (₹10 face value) for every 5 fully paid-up equity shares of Dhanuka Laboratories (₹100 face value). This 161:5 swap ratio is a crucial aspect for DLL shareholders.
What to Track Next
Investors should monitor the post-amalgamation performance of the combined entity and any announcements regarding the integration process. The record date of July 23, 2026, is critical for eligible shareholders.
Context Metrics (Time-bound)
- Effective Date: July 10, 2026
- Appointed Date: April 1, 2024
- Record Date: July 23, 2026
- Authorized Share Capital (Post-Amalgamation): ₹164.51 crore
- Share Exchange Ratio: 161 Orchid Pharma shares for every 5 Dhanuka Laboratories shares